Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

2 results

  • 13 - Contraceptionin the 40-somethings

  • Edited by Paula Briggs, Gabor Kovacs, Monash University, Victoria
  • Edited in consultation with John Guillebaud, University College London
  • Book: Contraception
  • Published online: 05 August 2013
  • Print publication: 11 July 2013, pp 111-119

  • Summary

    This chapter reviews the estimated thrombotic risks associated with the oestrogen content of combined hormonal contraception. Thrombotic diseases discussed in this chapter are arterial thrombosis and venous thrombosis. The risk of arterial thrombosis, including stroke and myocardial infarction, is reported to be increased in users of combined hormonal contraception. Such events may be fatal, or lead to disabling sequelae. While oestrogen may play a role in arterial thrombosis, the effect is primarily related to an interaction with traditional, and to some extent modifiable, risk factors for arterial disease. Venous thrombosis mostly manifests in the deep veins of the leg, but may occur in other sites, such as the upper extremities, cerebral sinus, liver and portal veins or retinal veins. The risk of venous thromboembolism (VTE) is strongly associated with age, obesity and in users of oral contraceptives (OCs). Pregnancy is a far more profound thrombophilia risk.